View All Blog Posts

Healthy Innovation Statement on COVID-19

Our thoughts are with those affected by the outbreak of COVID-19, the novel strain of the coronavirus, both here in Southeast Asia and around the globe. Addressing the global public health challenges presented by COVID-19 will require collaboration and partnership from stakeholders across the globe. Working together, governments, global health authorities and the private sector can develop solutions to diagnose, treat and prevent the further spread of COVID-19. Now, as always, policies that advance the benefits of healthy innovation are vital to solving public health crises.

For more information about how the industry is responding to the coronavirus crisis, please visit the International Federation of Pharmaceutical Manufacturers and Associations and the Pharmaceutical Research and Manufacturers of America.

Recent Blog Posts

The Regulatory Standards that Facilitate Quality Health Care Outcomes

Challenges in the global regulatory environment coupled with increased demand for patient access to new treatments have put pressure on authorities in Asia to strengthen regulatory processes. As Asia looks to further innovation and ensure new medicines can be made available to patients, strong regulatory systems and intellectual property protections will be critical.

New Report Urges ASEAN Markets to Strengthen Intellectual Property Rights

A new report by the Geneva Network urges countries in Southeast Asia to strengthen intellectual property (IP) protections to increase innovation and higher-value knowledge-based goods and services. The report also recommends that emerging markets align their IP systems with the highest global standards to attract foreign investors, integrate into global supply chains and support local businesses and entrepreneurs.